37results about How to "Enhance immune stimulation" patented technology

The invention provides methods for modulating the immune response caused by CpG-containing oligonucleotides. The methods according to the invention enable both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy applications.

The invention discloses probiotic solid powder and a preparation method thereof. The probiotic solid powder comprises a mixture of active probiotics and active zeolite, wherein the active probiotic content is between 12 and 50 billion colony-forming units (CFU)/gram; and the active zeolite mixture comprises the following components in percentage by weight: 30 to 50 percent of zeolite, 20 to 40 percent of attapulgite clay and 10 to 30 percent of bentonite. The probiotic solid powder provides a high-quality and low-cost antibiotic substitute product for livestock breeding; and the probiotic solid powder with 1 to 4 million CFU of live bacteria is added into each gram of feed, so the growth speed of chickens, pigs and fish can be improved by 2.0 to 15.6 percent, the conversion rate of the feed can be improved by 1.1 to 9.3 percent, and the diarrhea rate and the death rate of animals can be reduced obviously. The preparation method of the probiotic solid powder is simple, has low cost andcan reduce environmental pollution; and the content of the obtained product bacteria is high.

The present invention relates to a novel adjuvant system that generates an efficient immune response against antigens of various origins while reducing the risk of toxic side effects attendant to the use of known adjuvants. The novel adjuvant of the present invention comprises virosomes and allows antigenic molecules to be bound to or encapsulated in a variety of delivery vehicles which are easier to prepare for virosomes.

The present invention provides novel adjuvant systems for the potentiation of immune responses against antigenic targets.

The invention provides methods for modulating the immune response caused by CpG dinucleotide-containing compounds. The methods according to the invention enables both decreasing the immunostimulatory effect for antisense applications, as well as increasing the immunostimulatory effect for immunotherapy applications.

The use of therapeutically active lipids for organ/tissue-specific enrichment for the treatment of inflammatory, ischemic or degenerative disorders and/or for stimulating a regeneration is arranged and developed such that the lipids are bound on application to carrier molecules for which cell-specific uptake systems in the cells of the organs and/or tissue exist. In addition, a method of producing organ/tissue-specific therapeutically active lipids for treatment of inflammatory, ischemic or degenerative disorders and/or stimulation of a regeneration, in particular for treating inflammatory liver disorders, is claimed, which is arranged and developed such that lysophosphatidylethanolamine (LysoPE) is coupled to the carboxyl group of ursodeoxycholate (UrsoDOCA) converted to an ester to give a LysoPE-DOCA compound.

The present invention provides an adjuvant-polymer construct comprising a polymer backbone which is covalently linked to 3 or more adjuvants, wherein the 3 or more adjuvants are each present in a pendant side chain, the adjuvants being connected to the polymer backbone either directly or via a spacer group.

The invention relates to a preparation method and an application of a graphene-CpG. The preparation method is characterized by specifically comprising the steps of functionalizing the graphene, weighing 1mg of graphene and 5mg of PL-PEG5000-Amine (Biotin-Poly Ethylene Glycol) or PL-PEG2000-Amine and adding the two materials to a 20ml straight thick-wall glass tube, adding 5ml of distilled water to the 20ml straight thick-wall glass tube and putting the 20ml straight thick-wall glass tube in a shaker for shaking until DSPE-PEG (Distearoyl Phosphatidyl Ethanolamine-Poly Ethylene Glycol) is completely dissolved; centrifuging a graphene suspension at the room temperature for 3 hours at a rotating speed of 24000g and collecting the supernate, and recording the UV-VIS-NIR (Ultraviolet-Visual-Near Infrared) absorption spectrum of the obtained graphene solution, wherein the final concentration of the graphene is in a normal rang of 40-70mg/L; and preserving at 4 DEG C, and then bonding the graphene with an oligonucleotide CpG. The preparation method is unique and capable of obviously inhibiting the growth of the tumor of breast and the tumor of colorectum; compared with a PBS (Phosphate Buffer Solution) group, the graphene-CpG prepared by the preparation method disclosed by the invention has the advantages that the difference is significant and the growth of the tumors is obviously suppressed; besides, the preparation method has statistical significance.

The invention describes a therapeutic agent capable of treating and/or preventing rabbit haemorrhagic disease virus infection in rabbits, namely a recombinant parapoxvirus, characterized in that the VP60 major capsid protein from the rabbit haemorrhagic disease virus (RHDV) is expressed from a foreign nucleic acid.

The invention discloses a kit, method and application of a high-efficiency novel DC autovaccine, and belongs to the technical field of biology. The kit comprises a cytokine combination of GM-CSF, IL-4, FLT3-L and ATRA. According to the method, an existing GM-CSF+IL-4 cultivation technique is improved, is combined with FLT3-L to promote generation of pDC, mononuclear cells are increased to convert DC, generation of MDSC is inhibited by utilizing all-transretinoic acid (ATRA) to eliminate the negative adjustment effect of MDSC in preparation of DC vaccines, and an OK432 and CPH ODN co-stimulation mode is adopted to effectively promote mature of mDC and pDC and enhance the DC immunostimulation function.

The invention discloses a vaccine based on cyclodextrin grafted chitosan (CS-g-CD), a preparation method and application, and belongs to the field of biomedical engineering. Antigen molecules, immunologic stimulants and the like are combined with CS-g-CD in a subject-object self-assembly mode to form supramolecules, and the supramolecules can be further prepared into nano-particles through methods such as sodium tripolyphosphate to serve as vaccine drugs. The cyclodextrin grafted chitosan provided by the invention has better solubility, and the cyclodextrin modified on the cyclodextrin grafted chitosan provides host-guest binding sites, so that the cyclodextrin grafted chitosan can be more easily used for interacting with antigen molecules to form a high-stability self-assembled supramolecular vaccine preparation, and is beneficial to better in-vivo delivery and antigen storage, thereby being beneficial to improving the immune stimulation ability. The vaccine preparation prepared in a subject-object self-assembly mode can be used as a platform for vaccine development, and is suitable for wider vaccine development.

Amphiphilic oligonucleotide conjugates that enhance adjuvant function are disclosed. The conjugates typically include: a lipophilic component, and conjugated thereto (directly or indirectly) an immunomodulating oligonucleotide that, if it were not conjugated to the lipophilic component, would suppress TLR7 and/or TLR8 stimulation. In the presence of albumin, these conjugates significantly enhance adjuvant function, in particular the function of TLR7/8-mediated adjuvants such as an imidazoquinolinamine. The conjugates can be administered, along with an adjuvant compound, to a subject in order to cause and/or enhance an immune response (for instance, to an infectious agent or a cancer antigen) in the subject.

The present invention relates to bactericidal/permeability increasing protein (BPI) for use in a method of immunization of a patient, preferably as an adjuvant in a method of vaccination. The present invention also relates to a preparation comprising BPI for use in a method of immunization of a patient, and optionally an immunomodulatory agent. The present invention further relates to a process of producing a preparation including BPI for use in a method of immunization of a patient.

The invention discloses a compound microecological preparation for inhibiting pathogenic vibrio for breeding stichopus japonicus, which is prepared by mixing rhodopseudomonas palustris, clostridium butyricum, oak leaf extract and aloe leaf extract into a feed additive, and the addition amount of the rhodopseudomonas palustris, the clostridium butyricum, the oak leaf extract and the aloe leaf extract in each gram of feed is 105-107 cfu, 105-107 cfu, 1-2 mg and 4-8 mg; the preparation method of the oak leaf extract and the aloe leaf extract comprises the following steps: respectively cleaning oak leaves and aloe leaves with distilled water, and ventilating and drying in the shade at 25 DEG C; the preparation method comprises the following steps: respectively homogenizing and crushing oak leaves and aloe leaves by using a homogenizer, and adding an ethanol solution with the volume fraction of 65-85% according to the material-liquid ratio of 0.05-0.1 g/mL; extracting for 1-2.5 hours at normal temperature under the action of ultrasonic waves with the working frequency of 40 KHZ and the power of 80 W; and filling the extract into an ultrafiltration membrane device, filtering to remove impurities under the pressure condition of 0.06 Mpa, and carrying out vacuum concentration and freeze drying to obtain freeze-dried powder.

The invention provides an oil-in-water adjuvant used for animal vaccines and a preparation method for the oil-in-water adjuvant, and belongs to the technical field of biological product-like animal vaccines. The oil-in-water adjuvant used for the animal vaccines comprises the following raw materials by weight percent: 80.7%-89.5% of mineral oil, 2.1%-2.5% of span 80, 3.0%-5.3% of tween 85, 1.5%-3.5% of lauroyl macrogolglycerides, 0.5%-4.7% of polyglyceryl-6 caprylate and 2.2%-3.6% of polyoxyethylated castor oil. The oil-in-water adjuvant is simple and convenient to prepare, easy to obtain andlow in cost; prepared vaccines are low in viscosity, easy and safe to inject, stable in quality and small in grain size, can reach a nanoscale, and can induce temporary and permanent immunity; and theoil-in-water adjuvant is a safe adjuvant which can be used for poultry and livestock vaccines.

The invention provides a tumor vaccine based on injectable hydrogel as well as a preparation method and application of the tumor vaccine. The tumor vaccine is prepared from the following raw materials: a tumor antigen, an immunologic adjuvant, multi-arm polyethylene glycol and multi-aldehyde polysaccharide. The tumor vaccine can be constructed in a mild aqueous solution, can efficiently load tumor-associated antigens, adjuvants and the like, can protect the activity of the antigens, the adjuvants and the like, can maintain the stability of the antigens, the adjuvants and the like, realizes long-acting local slow release of the antigens and the adjuvants, and remarkably improves the immunostimulation effect.